The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.
 
Ke-Jing Tang
No Relationships to Disclose
 
Baogang Liu
No Relationships to Disclose
 
Yu Yao
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Jianying Zhou
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma (Inst)
 
Ping Sun
No Relationships to Disclose
 
Donglin Wang
No Relationships to Disclose
 
Dongqing Lv
No Relationships to Disclose
 
Huijie Wang
No Relationships to Disclose
 
Yi Hu
No Relationships to Disclose
 
Qiang Li
No Relationships to Disclose
 
Yujiao Song
No Relationships to Disclose
 
Grace Gao
No Relationships to Disclose
 
Liyun Wang
No Relationships to Disclose
 
Trishala Agrawal
No Relationships to Disclose
 
Archan Bhattacharya
No Relationships to Disclose
 
Mahadi Baig
No Relationships to Disclose
 
Patricia A Lorenzini
No Relationships to Disclose
 
Honeylet Wortman-Vayn
No Relationships to Disclose
 
Caicun Zhou
Consulting or Advisory Role - Hengrui Pharmaceutical; Innovent Biologics; QiLu Pharmaceutical; TopAlliance BioSciences Inc
Speakers' Bureau - Alice's Arc; Amoy Diagnostics; Anheart Therapeutics; CStone Pharmaceuticals; Hengrui Pharmaceutical; Innovent Biologics; Lilly; Luye Pharma; MSD; QiLu Pharmaceutical; Roche; Sanofi; TopAlliance BioSciences Inc